5,150 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 5,150 shares of the medical research company’s stock, valued at approximately $951,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Norges Bank purchased a new position in Charles River Laboratories International in the 4th quarter worth $98,886,000. Wellington Management Group LLP increased its holdings in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after purchasing an additional 335,658 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth about $42,776,000. Cooke & Bieler LP lifted its holdings in shares of Charles River Laboratories International by 42.1% during the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after purchasing an additional 126,372 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $136.95 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a fifty day moving average of $162.49 and a 200 day moving average of $180.59. The firm has a market cap of $7.00 billion, a PE ratio of 912.99, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a one year low of $132.99 and a one year high of $258.56.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 earnings per share. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of several research reports. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. UBS Group reissued a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).